

Vyvgart (efgartigimod alfa-fcab)
Effective 09/01/2022

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Vyvgart is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Coverage Guidelines

Authorization may be reviewed for members new to the plan who are currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Member has a diagnosis of generalized myasthenia gravis (gMG)
2. Positive serologic test for anti-acetylcholine receptor antibodies
3. Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV
4. Member is ≥ 18 years of age
5. Prescriber by or in consultation with a neurologist
6. MG activities of daily living (MG-ADL) total score of 5 or more with at least 50% of the score due to non-ocular symptoms
7. Member is currently on a stable dose of at least ONE of the following:
 - a. Acetylcholinesterase inhibitors (e.g., pyridostigmine)
 - b. Corticosteroids
 - c. Nonsteroidal immunosuppressive therapy (NSIST) (e.g., azathioprine, mycophenolate mofetil)

Continuation of Therapy

Reauthorization requires physician attestation that member demonstrates a positive response to therapy (e.g., improvement in MG-ADL score, changes compared to baseline in Quantitative Myasthenia Gravis (QMG) total score).

Limitations

1. Initial approvals and reauthorizations will be granted for 6 months.

Review History

07/20/22 – Reviewed and created for July P&T. Effective 09/01/2022

References

1. Vyvgart [package insert]. Boston, MA: Argenx US, Inc.; December 2021.
2. Sanders D, Wolfe G, Benatar M et al. International consensus guidance for management of myasthenia gravis. *Neurology*. 2021; 96 (3) 114-122.

Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol*. 2021. 20:526-536.

